Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors.

Brooks ED, Schoenhals JE, Tang C, Micevic G, Gomez DR, Chang JY, Welsh JW.

Cancer J. 2016 Jul-Aug;22(4):257-66. doi: 10.1097/PPO.0000000000000210. Review.

2.

β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.

Thompson PA, O'Brien SM, Xiao L, Wang X, Burger JA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG.

Cancer. 2016 Feb 15;122(4):565-73. doi: 10.1002/cncr.29794. Epub 2015 Nov 20.

3.

Proteomic landscape of bronchoalveolar lavage fluid in human immunodeficiency virus infection.

Nguyen EV, Gharib SA, Crothers K, Chow YH, Park DR, Goodlett DR, Schnapp LM.

Am J Physiol Lung Cell Mol Physiol. 2014 Jan 1;306(1):L35-42. doi: 10.1152/ajplung.00140.2013. Epub 2013 Nov 8.

4.
5.

Exogenous control of the expression of Group I CD1 molecules competent for presentation of microbial nonpeptide antigens to human T lymphocytes.

Aquino A, Graziani G, Franzese O, Prete SP, Bonmassar E, Bonmassar L, D'Atri S.

Clin Dev Immunol. 2011;2011:790460. doi: 10.1155/2011/790460. Epub 2011 Mar 22. Review.

6.

Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis.

Balakumaran A, Robey PG, Fedarko N, Landgren O.

Expert Rev Mol Diagn. 2010 May;10(4):465-80. doi: 10.1586/erm.10.31. Review.

7.

Linking mechanistic and behavioral responses to sublethal esfenvalerate exposure in the endangered delta smelt; Hypomesus transpacificus (Fam. Osmeridae).

Connon RE, Geist J, Pfeiff J, Loguinov AV, D'Abronzo LS, Wintz H, Vulpe CD, Werner I.

BMC Genomics. 2009 Dec 15;10:608. doi: 10.1186/1471-2164-10-608.

8.

Dendritic cells treated with resveratrol during differentiation from monocytes gain substantial tolerogenic properties upon activation.

Svajger U, Obermajer N, Jeras M.

Immunology. 2010 Apr;129(4):525-35. doi: 10.1111/j.1365-2567.2009.03205.x. Epub 2009 Nov 25.

9.

Beta2-microglobulin as a potential factor for the expansion of mesenchymal stem cells.

Zhu Y, Su Y, Cheng T, Chung LW, Shi C.

Biotechnol Lett. 2009 Sep;31(9):1361-5. doi: 10.1007/s10529-009-0027-0. Epub 2009 May 23.

10.

Bone marrow microenvironment and the identification of new targets for myeloma therapy.

Podar K, Chauhan D, Anderson KC.

Leukemia. 2009 Jan;23(1):10-24. doi: 10.1038/leu.2008.259. Epub 2008 Oct 9. Review.

11.

Immune therapies.

Prabhala RH, Munshi NC.

Hematol Oncol Clin North Am. 2007 Dec;21(6):1217-30, x-xi. Review.

13.

Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma.

Wang S, Yang J, Qian J, Wezeman M, Kwak LW, Yi Q.

Blood. 2006 Mar 15;107(6):2432-9. Epub 2005 Nov 15.

14.

Dysfunctional T regulatory cells in multiple myeloma.

Prabhala RH, Neri P, Bae JE, Tassone P, Shammas MA, Allam CK, Daley JF, Chauhan D, Blanchard E, Thatte HS, Anderson KC, Munshi NC.

Blood. 2006 Jan 1;107(1):301-4. Epub 2005 Sep 8.

15.

Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome.

Gottenberg JE, Busson M, Cohen-Solal J, Lavie F, Abbed K, Kimberly RP, Sibilia J, Mariette X.

Ann Rheum Dis. 2005 Jul;64(7):1050-5. Epub 2005 Jan 7.

Supplemental Content

Support Center